178 related articles for article (PubMed ID: 9250826)
1. Disease progression in patients with multiple myeloma is associated with a concurrent alteration in the expression of both oncogenes and tumour suppressor genes and can be monitored by the oncoprotein phenotype.
Pope B; Brown R; Luo XF; Gibson J; Joshua D
Leuk Lymphoma; 1997 May; 25(5-6):545-54. PubMed ID: 9250826
[TBL] [Abstract][Full Text] [Related]
2. The oncoprotein phenotype of plasma cells from patients with multiple myeloma.
Brown RD; Pope B; Luo XF; Gibson J; Joshua D
Leuk Lymphoma; 1994 Dec; 16(1-2):147-56. PubMed ID: 7696921
[TBL] [Abstract][Full Text] [Related]
3. Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: indications for different disease entities.
Rasmussen T; Theilgaard-Mönch K; Hudlebusch HR; Lodahl M; Johnsen HE; Dahl IM
Br J Haematol; 2003 Oct; 123(2):253-62. PubMed ID: 14531906
[TBL] [Abstract][Full Text] [Related]
4. C-MAF oncogene dysregulation in multiple myeloma: frequency and biological relevance.
Rasmussen T; Knudsen LM; Dahl IM; Johnsen HE
Leuk Lymphoma; 2003 Oct; 44(10):1761-6. PubMed ID: 14692531
[TBL] [Abstract][Full Text] [Related]
5. The functional phenotype of the primitive plasma cell in patients with multiple myeloma correlates with the clinical state.
Pope B; Brown RD; Gibson J; Petersen A; Wiley J; Joshua DE
Leuk Lymphoma; 1997 Sep; 27(1-2):83-91. PubMed ID: 9373199
[TBL] [Abstract][Full Text] [Related]
6. Antisense p53 transduction leads to overexpression of bcl-2 and dexamethasone resistance in multiple myeloma.
Iyer R; Ding L; Batchu RB; Naugler S; Shammas MA; Munshi NC
Leuk Res; 2003 Jan; 27(1):73-8. PubMed ID: 12479855
[TBL] [Abstract][Full Text] [Related]
7. Elevated c-myc messenger RNA in multiple myeloma cell lines.
Fourney R; Palmer M; Ng A; Dietrich K; Belch A; Paterson M; Brox L
Dis Markers; 1990; 8(3):117-24. PubMed ID: 1980237
[TBL] [Abstract][Full Text] [Related]
8. Oncogenes in multiple myeloma: point mutation of N-ras.
Paquette RL; Berenson J; Lichtenstein A; McCormick F; Koeffler HP
Oncogene; 1990 Nov; 5(11):1659-63. PubMed ID: 2267133
[TBL] [Abstract][Full Text] [Related]
9. Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease.
Kristensen IB; Christensen JH; Lyng MB; Møller MB; Pedersen L; Rasmussen LM; Ditzel HJ; Abildgaard N
Br J Haematol; 2013 May; 161(3):373-82. PubMed ID: 23431957
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow expression of CCL3 is not correlated with the extent of lytic bone lesions.
Cohen Y; Gutwein O; Garach-Jehoshua O; Bar-Haim A; Kornberg A
Acta Haematol; 2014; 132(2):129-33. PubMed ID: 24556596
[No Abstract] [Full Text] [Related]
11. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
Alzrigat M; Párraga AA; Agarwal P; Zureigat H; Österborg A; Nahi H; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2017 Feb; 8(6):10213-10224. PubMed ID: 28052011
[TBL] [Abstract][Full Text] [Related]
12. Expression of the c-myc proto-oncogene in multiple myeloma and chronic lymphocytic leukemia: an in situ analysis.
Greil R; Fasching B; Loidl P; Huber H
Blood; 1991 Jul; 78(1):180-91. PubMed ID: 2070052
[TBL] [Abstract][Full Text] [Related]
13. CD229 Expression on Bone Marrow Plasma Cells from Patients with Multiple Myeloma and Monoclonal Gammopathies of Uncertain Significance.
Carulli G; Buda G; Azzarà A; Ciancia EM; Sammuri P; Domenichini C; Guerri V; Petrini M
Acta Haematol; 2016; 135(1):11-4. PubMed ID: 26303094
[No Abstract] [Full Text] [Related]
14. Altered expression of growth-regulated protooncogenes in human malignant plasma cells.
Palumbo AP; Pileri A; Dianzani U; Massaia M; Boccadoro M; Calabretta B
Cancer Res; 1989 Sep; 49(17):4701-4. PubMed ID: 2667753
[TBL] [Abstract][Full Text] [Related]
15. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.
Rasche L; Chavan SS; Stephens OW; Patel PH; Tytarenko R; Ashby C; Bauer M; Stein C; Deshpande S; Wardell C; Buzder T; Molnar G; Zangari M; van Rhee F; Thanendrarajan S; Schinke C; Epstein J; Davies FE; Walker BA; Meissner T; Barlogie B; Morgan GJ; Weinhold N
Nat Commun; 2017 Aug; 8(1):268. PubMed ID: 28814763
[TBL] [Abstract][Full Text] [Related]
16. Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myeloma.
Chim CS; Liang R; Leung MH; Kwong YL
J Clin Pathol; 2007 Jan; 60(1):104-6. PubMed ID: 17213358
[TBL] [Abstract][Full Text] [Related]
17. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis.
Davies FE; Dring AM; Li C; Rawstron AC; Shammas MA; O'Connor SM; Fenton JA; Hideshima T; Chauhan D; Tai IT; Robinson E; Auclair D; Rees K; Gonzalez D; Ashcroft AJ; Dasgupta R; Mitsiades C; Mitsiades N; Chen LB; Wong WH; Munshi NC; Morgan GJ; Anderson KC
Blood; 2003 Dec; 102(13):4504-11. PubMed ID: 12947006
[TBL] [Abstract][Full Text] [Related]
18. Deletion of the retinoblastoma gene in multiple myeloma.
Dao DD; Sawyer JR; Epstein J; Hoover RG; Barlogie B; Tricot G
Leukemia; 1994 Aug; 8(8):1280-4. PubMed ID: 8057662
[TBL] [Abstract][Full Text] [Related]
19. [Molecular analysis of multiple myeloma cells].
Yasuga Y; Hirosawa S
Nihon Rinsho; 1995 Mar; 53(3):564-7. PubMed ID: 7699886
[TBL] [Abstract][Full Text] [Related]
20. The neural cell adhesion molecule NCAM in multiple myeloma.
Kaiser U; Auerbach B; Oldenburg M
Leuk Lymphoma; 1996 Feb; 20(5-6):389-95. PubMed ID: 8833394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
